Bioptimus
PrivateLast Round
Series A
Jan 14, 2025
Total Funding Raised
$76M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Bioptimus operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series A round in January 2025.
Bioptimus is a biotechnology and artificial intelligence company that develops a universal AI foundation model to enhance scientific research and drive biotechnological innovation by transforming multiscale biological data into actionable insights.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS, Data as a Service
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bioptimus Comparables
Compare Bioptimus with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chan Zuckerberg Biohub | 82% | |
| Tahoe Therapeutics | 81% | |
| Aignostics | 79% |
For institutional investors. Book with your work email.
Bioptimus Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 14, 2025 | ||||
| Seed | Feb 20, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bioptimus Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boom Capital Ventures | Series A |
| Top Harvest Capital | Seed |
| HV Fund | Series A |
| NJF Capital | Seed |
| Andera Partners | Series A |
| Top Harvest Capital | Seed |
| Pomifer Capital Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 40% MoM, reaching 19K.
- Jul 20, 2026
Open roles increased to 63, 3.4x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 7, 2026
Bioptimus is constructing a universal AI foundation model that connects biology across molecules, cells, tissues, and organs to advance scientific and medical discovery, with research institutions and clinical partners contributing to its multimodal biology model.
- partners_withAug 20, 2026
Bioptimus partners with Cancer Research Horizons to give Bioptimus access to a multimodal colorectal cancer dataset from more than 1,750 patients for training and evaluating its biological foundation model in France on Aug 20th '26.
- launchesAug 16, 2026
Bioptimus unveils a supersized open-source AI model for disease research and diagnosis.
For institutional investors. Book with your work email.
Bioptimus Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bioptimus's valuation, stock price, and market status.
Is Bioptimus a public or private company?
Bioptimus is a private company.
What is the current stock price of Bioptimus?
Bioptimus is a private company, so its shares have no public market price. Caplight tracks Bioptimus's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bioptimus worth (valuation)?
Valuation information for Bioptimus is not publicly available.
Can I buy Bioptimus stock?
Bioptimus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bioptimus's last funding round?
Bioptimus's most recent funding round was Series A on January 14, 2025.
Who are the main investors in Bioptimus?
Key investors in Bioptimus include Sofinnova Partners, Bpifrance, Cathay Innovation.
Will Bioptimus IPO soon?
No public IPO plans have been announced for Bioptimus.
How can I track Bioptimus secondary market activity?
Caplight tracks bids, offers, and trades in Bioptimus's shares on secondary markets.